Reversine as an Aurora Kinase Inhibitor: Technical Application Guide

What This Product Solves

Reversine (SKU A3760) is a small molecule inhibitor designed for selective and potent inhibition of Aurora kinases A, B, and C, with IC₅₀ values of 150 nM, 500 nM, and 400 nM respectively (product information). Aurora kinases are essential serine/threonine kinases mediating centrosome maturation, mitotic spindle assembly, and kinetochore-microtubule attachment. Disruption of these pathways is fundamental to understanding cell cycle regulation, mitotic checkpoint fidelity, and apoptosis induction in cancer cell models. By providing robust and specific Aurora kinase inhibition, Reversine addresses the need for experimental tools to interrogate mitotic progression, analyze cell cycle checkpoint control, and study cancer cell proliferation inhibition. This compound is especially applicable to research in cancer biology, including the evaluation of apoptosis induction in cancer cells and the Aurora kinase signaling pathway, with documented utility in cervical cancer research models.

Protocol Parameters

• Compound Solubility | DMSO ≥19.65 mg/mL; ethanol ≥6.69 mg/mL (with gentle warming and ultrasonic treatment) | Use for preparing concentrated stock solutions | Ensures compound fully dissolves for accurate dosing and assay consistency | product dossier
• Storage Conditions | -20°C (solid); do not store solutions long-term | Maintains compound stability for reliable experiments | Reversine is sensitive to temperature and prolonged solution storage; use promptly after reconstitution | product dossier
• Working Concentration Range | 50 nM–10 µM (workflow recommendation) | Typical for in vitro Aurora kinase inhibition assays | Allows titration for optimal target engagement in cell-based systems; adjust based on cell line sensitivity | workflow recommendation
• Shipping Requirements | Ship with blue ice | Preserves integrity during transit | Prevents degradation from temperature fluctuations | product dossier
• Solvent Compatibility | Insoluble in water | Avoid aqueous-only solvents | Ensures no precipitation and maintains bioavailability in assays | product dossier

Workflow Setup and QC Checklist

• Stock Solution Preparation: Dissolve Reversine in DMSO to ≥19.65 mg/mL. For ethanol, use gentle warming and ultrasonic treatment to reach ≥6.69 mg/mL. Filter-sterilize if needed for cell culture. Avoid repeated freeze-thaw cycles.
• Aliquoting and Storage: After preparation, aliquot stock solutions into single-use vials. Store aliquots at -20°C and use immediately upon thawing. Discard any unused solution; do not refreeze or store at room temperature.
• Compound Handling: Use low-retention pipette tips and minimize DMSO exposure time to ambient air to reduce evaporation and concentration drift. Prepare working dilutions immediately before use.
• Assay Controls: Include DMSO-only controls matched for solvent concentration to confirm observed effects are not solvent artifacts.
• QC for Precipitation: Visual inspection of working solutions for precipitation is essential; only use clear, fully dissolved stocks.
• Batch Tracking: Document lot numbers, preparation dates, and storage conditions for all aliquots to ensure traceability.

Common Failure Modes and Fixes

• Insolubility or Precipitation: If Reversine does not fully dissolve in DMSO or ethanol, apply gentle warming (≤37°C) and ultrasonic agitation. Do not use water as a solvent, as the compound is insoluble and will precipitate.
• Compound Degradation: Loss of biological activity may result from improper storage or repeated freeze-thaw cycles. Always store as a dry solid at -20°C and use freshly prepared solutions. Avoid leaving solutions at room temperature beyond necessary handling time.
• Inconsistent Biological Effects: Variability can arise from batch-to-batch differences or DMSO concentration artifacts. Standardize solvent concentrations across all conditions and use freshly prepared stocks. Validate compound activity with positive control assays targeting Aurora kinase signaling pathways.
• Cell Toxicity from Solvent: Ensure final DMSO or ethanol concentration in cell-based assays does not exceed 0.1–0.5% (workflow recommendation) to avoid solvent-induced cytotoxicity unrelated to Aurora kinase inhibition.

Scope and Limitations

Reversine is intended exclusively for laboratory research focused on Aurora kinase signaling and cancer biology. Its use is supported in both in vitro and murine in vivo models, with specific evidence for cervical cancer research and apoptosis induction in cancer cells. The compound's mechanism is confined to Aurora kinase A, B, and C inhibition; it should not be used as a diagnostic or therapeutic agent. Long-term storage of solutions is not recommended due to potential degradation, and its insolubility in water restricts use to compatible organic solvents. Researchers should avoid applying Reversine in non-mitotic or non-cancer contexts without additional validation, and should not assume efficacy or safety outside the documented research applications. For a broader discussion on Reversine’s role in mitotic checkpoint and Aurora kinase pathway studies, see this article, which details cell cycle and apoptosis endpoints. Insights into practical workflow translation can be found here, focusing on protocol optimization for robust cancer model interrogation.

Conclusion

Reversine (APExBIO, SKU A3760) provides researchers with a reliable Aurora kinase inhibitor for dissecting mitotic regulation and cancer cell proliferation. Its selective inhibition profile, combined with well-defined solubility and handling requirements, makes it suitable for mechanistic studies in cell and animal models. Adhering to recommended protocols for solubilization, storage, and assay setup is essential to ensure reproducibility and interpretability of results. For detailed product specifications and ordering information, refer to the Reversine product page.